This company listing is no longer active
Destiny Pharma Future Growth
Future criteria checks 0/6
Destiny Pharma's revenue and earnings are forecast to decline at 171.4% and 15.5% per annum respectively while EPS is expected to decline by 13.6% per annum.
Key information
-15.5%
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 42.4% |
Revenue growth rate | -171.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Jul 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | -8 | N/A | N/A | 1 |
12/31/2024 | N/A | -6 | -6 | -5 | 2 |
12/31/2023 | 1 | -6 | -6 | -5 | N/A |
9/30/2023 | 1 | -6 | -5 | -5 | N/A |
6/30/2023 | 1 | -6 | -5 | -5 | N/A |
3/31/2023 | 1 | -6 | -6 | -6 | N/A |
12/31/2022 | 0 | -7 | -6 | -6 | N/A |
9/30/2022 | 0 | -6 | -5 | -5 | N/A |
6/30/2022 | 0 | -6 | -5 | -5 | N/A |
3/31/2022 | 0 | -6 | -5 | -5 | N/A |
12/31/2021 | 0 | -5 | -5 | -5 | N/A |
9/30/2021 | 0 | -5 | -7 | -6 | N/A |
6/30/2021 | 0 | -5 | -9 | -6 | N/A |
3/31/2021 | 0 | -5 | -8 | -6 | N/A |
12/31/2020 | 0 | -5 | -8 | -5 | N/A |
9/30/2020 | 0 | -5 | -6 | -5 | N/A |
6/30/2020 | 0 | -5 | -4 | -4 | N/A |
3/31/2020 | 0 | -5 | -4 | -4 | N/A |
12/31/2019 | 0 | -5 | -5 | -5 | N/A |
9/30/2019 | 0 | -5 | -5 | -5 | N/A |
6/30/2019 | N/A | -5 | -6 | -6 | N/A |
3/31/2019 | N/A | -5 | -5 | -5 | N/A |
12/31/2018 | N/A | -5 | -5 | -5 | N/A |
9/30/2018 | N/A | -5 | -4 | -4 | N/A |
6/30/2018 | N/A | -4 | -3 | -3 | N/A |
3/31/2018 | N/A | -4 | -3 | -3 | N/A |
12/31/2017 | N/A | -3 | -2 | -2 | N/A |
9/30/2017 | N/A | -2 | N/A | -2 | N/A |
6/30/2017 | N/A | -2 | N/A | -1 | N/A |
3/31/2017 | N/A | -1 | N/A | -1 | N/A |
12/31/2016 | N/A | -1 | N/A | -1 | N/A |
12/31/2015 | N/A | -1 | N/A | -1 | N/A |
12/31/2014 | N/A | -2 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: D89 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: D89 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: D89 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: D89 is forecast to have no revenue next year.
High Growth Revenue: D89 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if D89's Return on Equity is forecast to be high in 3 years time